줄기세포 공동 연구 및 라이선싱 계약(2010-2025년)

Stem Cell Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the stem cell deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of stem cell deals from 2010 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter stem cell deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 533 stem cell deals announced since 2010 including financial terms where available including links to online deal records of actual stem cell partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of stem cell dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in stem cell dealmaking since 2010.

Chapter 3 provides an overview of the leading stem cell deals since 2010. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in stem cell dealmaking with a brief summary followed by a comprehensive listing of stem cell deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of stem cell deals signed and announced since Jan 2010, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of stem cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific stem cell technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in stem cell deal making since 2010.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Stem Cell Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2010
• Browse stem cell collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Stem Cell Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of stem cell trends and structure of deals entered into by leading biopharma companies worldwide.

Stem Cell Collaboration and Licensing Deals includes:

• Trends in stem cell dealmaking in the biopharma industry
• Directory of stem cell deal records covering pharmaceutical and biotechnology
• The leading stem cell deals by value
• Most active stem cell licensing dealmakers
• Stem Cell Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in stem cell dealmaking

• 2.1. Introduction
• 2.2. Stem cell deals over the years
• 2.3. Most active stem cell dealmakers
• 2.4. Stem cell deals by deal type
• 2.5. Stem cell deals by therapy area
• 2.6. Stem cell deals by industry sector
• 2.7. Deal terms for stem cell deals
  • 2.7.1 Stem cell deals headline values
  • 2.7.2 Stem cell deal upfront payments
  • 2.7.3 Stem cell deal milestone payments
  • 2.7.4 Stem cell royalty rates

Chapter 3 - Leading stem cell deals

• 3.1. Introduction
• 3.2. Top stem cell deals by value

Chapter 4 - Most active stem cell dealmakers

• 4.1. Introduction
• 4.2. Most active stem cell dealmakers
• 4.3. Most active stem cell deals company profiles

Chapter 5 - Stem cell contracts dealmaking directory

• 5.1. Introduction
• 5.2. Stem cell contracts dealmaking directory

Chapter 6 - Stem cell dealmaking by technology type

• Deal directory
• Deal directory - Stem cell deals by company A-Z
• Deal directory - Stem cell deals by deal type
• Deal directory - Stem cell deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Stem cell deals since 2010
• Figure 2: Active stem cell dealmaking activity - 2010 - 2025
• Figure 3: Stem cell deals by deal type since 2010
• Figure 4: Stem cell deals by therapy area since 2010
• Figure 5: Stem cell deals by industry sector since 2010
• Figure 6: Stem cell deals with a headline value
• Figure 7: Stem cell deals with an upfront value
• Figure 8: Stem cell deals with a milestone value
• Figure 9: Stem cell deals with a royalty rate value
• Figure 10: Top stem cell deals by value since 2010
• Figure 11: Most active stem cell dealmakers 2010 - 2025
• Figure 12: Stem cell deals by technology type since 2010